Cargando…
1397. Long term impact of the 13-valent pneumococcal conjugate vaccine use in infant immunization program on all-cause pneumonia hospitalizations in British Columbia, Canada: a time series analysis
BACKGROUND: Pneumonia is a leading cause of hospitalization and in-patient mortality globally. We determined the impact of 13-valent pneumococcal conjugate vaccine (PCV13) use on all-cause pneumonia hospitalization rates eight years after the vaccine was introduced in British Columbia, Canada. METHO...
Autores principales: | Vadlamudi, Nirma Khatri, Patrick, David M, Hoang, Linda, Rose, Caren, Sadatsafavi, Mohsen, Marra, Fawziah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776874/ http://dx.doi.org/10.1093/ofid/ofaa439.1579 |
Ejemplares similares
-
2701. The Impact of Infant 13-valent Conjugate Pneumococcal Vaccination Program on Invasive Pneumococcal Disease in Children in British Columbia, Canada
por: Vadlamudi, Nirma K, et al.
Publicado: (2019) -
2706. Indirect Effects of Infant 13-valent Conjugate Pneumococcal Vaccination Program on Invasive Pneumococcal Disease in Adults in British Columbia, Canada
por: Vadlamudi, Nirma K, et al.
Publicado: (2019) -
Incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate pneumococcal vaccine in British Columbia: A retrospective cohort study
por: Vadlamudi, Nirma Khatri, et al.
Publicado: (2020) -
2705. Serotype Replacement Following Childhood Pneumococcal Conjugate Vaccination Programs in British Columbia, Canada
por: Vadlamudi, Nirma K, et al.
Publicado: (2019) -
Efficacy and Safety of the Pneumococcal Conjugate-13 Valent Vaccine in Adults
por: Marra, Fawziah, et al.
Publicado: (2019)